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Purpose: To assess the response in spinal cord injured patients alternatively treated with 
different types and dosages of Botulinum neurotoxin type A (BoNT/A) over 15 years.
Material and methods: Patients who underwent first BoNT/A from 1999-2001 and prac-
ticed intermittent catheterization were included. Baseline 3-day bladder diary (BD) and 
urodynamics were collected. BoNT/A failure was defined when patients asked for re-
injection ≤ 3 months post-treatment. Criteria for re-injection was at least one daily epi-
sode of urinary incontinence at BD. Before re-injection, patients were asked if they had 
reached 6 months of dryness without antimuscarinics (YES response).
Results: Overall, 32/60 (53.4%) “No failure” (NF) group; 16 (26.6%) “occasional failure” 
(OF) and 12 (20%) “consecutive failure” (CF) were included. A total of 822 BoNT/A 
infiltrations were performed. The mean interval from previous injection to treatment 
re-scheduling was 8 months. No significant differences between treatments were found 
within the three groups (p>0.05).
The percentage of YES responses increased from 19% (AboBoNT/A 500IU) to 29 % 
(OnaBoNT/A 300IU) in NF, and from 18% (AboBoNT/A 500IU) to 25% (OnaBoNT/A 
300IU) for OF. Five NF cases (15.6%) maintained 6 months of dryness after each injec-
tion. Among the baseline variables, only low compliance (< 20mL/cmH
2
O) was found as 
predictor for failure (p=0.006).
Conclusions: Long term BoNT/A for NDO did not increase failures, independent of the types 
of treatments and switching. Definition of failure and other criteria for continuing repetitive 
BoNT/A treatment is mandatory. CF was predictable for no response in earlier follow-up.
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INTRODUCTION
One of the major health problems in pa-
tients with spinal cord injury (SCI) is bladder dys-
function. Particularly, the presence of neurogenic 
detrusor overactivity (NDO) may be a threat to the 
upper urinary tract (1-3).
 In 2000, Schurch et al. first published on 
detrusor botulinum neurotoxin type A (BoNT/A) 
injections to treat NDO in SCI individuals (4). 
Since then, literature reports a high percentage 
of patients who have gained clinical and urody-
namic benefits after BoNT/A, achieving urinary 
continence, increasing bladder capacity, reducing 
detrusor pressures in patients refractory to anti-
muscarinics (5-8). Both BoNT/A injections, Abob-
otulinumtoxin (Dysport®, Ipsen Biopharm, Slough, 
UK) as well as Onabotulinumtoxin (Botox®, Aller-
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gan, Irvine, CA, USA), have been proven to be safe 
with a positive impact on quality of life (9-15).
 Other BoNT/A such as NT-201 (Xeomin®) or 
CBTX-A distributed under several different brand 
names in different countries (Prosigne®, Lanzox®, 
Lantox®, Liftox®, and Redux®) have been studied 
by some authors, but evidence in literature is still 
lower compared to the Abo and OnaBoNT/A (16).
 Nevertheless, only OnaBoNT/A 200IU has 
been approved for NDO since 2013 in our country 
(17).
 However, not much information is avail-
able on follow-up longer than 10 years, especial-
ly taking into account the switching of BoNT/A 
types (Dysport® vs. Botox® or vice versa) and/or 
different dosages in the same cohort of patients 
over time.
Aim of the study
 In this retrospective study, we report 
the experience of our patients affected by NDO, 
treated with two types of BoNT/A (Botox® and/
or Dysport®) at different dosages during a 15-year 
follow-up.
MATERIAL AND METHODS
 Only adult SCI patients who had under-
gone the first BoNT/A injection for their NDO re-
fractory and/or intolerant to antimuscarinics, and 
who were managing their bladder via intermittent 
catheterization were selected in our Italian Centre. 
Only NDO exclusively secondary to SCI were in-
cluded. The study was conducted in accordance to 
the Declaration of Helsinki and the International 
Guidelines on Good Clinical Practice.
 From December 1999 to October 2001 the 
first injection was administered with two different 
BoNT/A at various dosages: AboBoNT/A (Dysport®) 
500 or 750IU and OnaBoNT/A (Botox®) 200 or 
300IU.
 Before the first injection and throughout 
the entire follow-up, a 3-day bladder diary (BD) 
was collected. At baseline, each subject was sub-
mitted to urodynamics as recommended by the 
International Continence Society (18).
 The interval between the previous injec-
tion and scheduling the patient’s following injec-
tion was also recorded. We evaluated the BD at 
the time of rescheduling for a new injection. If 
unable to attend our clinic, patients were advised 
to send us their BD by any means of communica-
tion (e.g, fax, post and/or mail).
 BoNT/A “failure” was defined as patients, 
within 3 months post-injection, who reported at 
least one daily episode of urinary incontinence in 
their BD.
 If ineffectual, the following repeated in-
jection was offered with the same dosage and 
type of BoNT/A previously used. Only after two 
consecutive failed attempts, a different type of 
BoNT/A and/or higher dosage were chosen ran-
domly.
 All those responding to the other 3 treat-
ments were switched to OnaBoNT/A 200IU after 
its approval in Italy in March 2013. Those pa-
tients continued with OnaBoNT/A (Botox®) 200IU 
unless they had two consecutive “failures”.
 The urodynamic parameters were: maxi-
mum detrusor pressure during involuntary con-
traction (Pdetmax), maximum cystometric capac-
ity (MCC), and bladder compliance (Pdet at MCC).
 After baseline, urodynamics pre re-in-
jection was mandatory only when BoNT/A fail-
ure occurred.
 Apart from failures, time for further uro-
dynamic follow-ups was scheduled according to 
the International Guidelines depending on the in-
dividual’s risk for upper urinary tract deteriora-
tion but never exceeding 2 years (19).
 Individuals taking antimuscarinics were 
advised to progressively stop the dosages if dry-
ness was achieved and then start again if urinary 
incontinence occurred.
 Prior to each new BoNT/A, the number of 
YES responses concerning the question on wheth-
er patients were continuously dry for at least 6 
months without oral drugs, was recorded.
 Subjects showing three consecutive fail-
ures were advised to undergo major surgery. For 
those subjects, data were reported from the first 
baseline up to the last injection. No BoNT/A treat-
ment was ever performed before 3 months had 
elapsed from previous injections.
 Detrusor infiltrations were performed on 
20-30 sites, trigone and bladder neck sparing, 
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with a 5mm 23 gauche needle and a rigid cysto-
scope only by experienced urologists.
 The following baseline predictable vari-
ables were taken into account: ≥ 40 years old; SCI 
>3 years; traumatic aetiology; gender; tetraplegia; 
complete lesion; concomitant antimuscarinics; 
compliance <20mL/cmH
2
O; urinary incontinence 
episodes ≥ 4 per day and mean bladder capacity > 
250mL at the BD.
Statistical analysis
 Statistical analyses were performed us-
ing the R software [R Core Team (2016)]. In 
particular, Kruskal-Wallis one-way analysis of 
variance was carried out to test differences in 
the duration of the efficacy in the three groups 
of patients defined, regardless of the treatment 
used (kruskal function of the R package ‘ag-
ricolae’ version 1.2). Similarly, differences in 
duration of efficacy across the four treatments 
here considered were tested for each group of 
patients. Moreover, the efficacy of the four 
treatments was evaluated using Linear Mixed-
Effects Models with random intercept and the 
log-likelihood function (lme function of the 
‘nlme’ R package version 3.1).
 The predictable variables were assessed 
using a Multinomial Log-linear Model (multi-




 From our database, a total of 72 SCI pa-
tients, of whom 19 female (26.4%), was initial-
ly identified. Twelve individuals (16.6%) were 
excluded: 4 due to missing data, 4 because of 
documented mixed urinary incontinence, 2 who 
were under 18 years old, and 2 who showed 
epilepsy as another neurological co-morbidity.
 A total of 60 patients (83.3%) were in-
cluded. Overall the SCI population had suprasa-
cral lesion ≤ thoracic (T11) level and exclusively 
A or B degree lesions according to the Ameri-
can Spinal Injury Association Impairment Scale 
(AIS) (20).
 All subjects reported at least 2 daily 
episodes of urinary incontinence in their BD 
at baseline. Individuals were sub-grouped in: 
“No Failure,” group (NF) who never reported 
BoNT/A injection “ineffectiveness” according 
to our criteria; “Occasional Failure” (OF) who 
had at least one, but not successive failures; 
“Consecutive Failure” (CF) subjects with persis-
tent BoNT/A ineffectiveness.
No failure group
 Thirty-two out of 60 SCL patients 
(53.3%) were defined as No Failure (NF). The 
mean duration of efficacy in months for each 
BoNT/A treatment is reported in Figure-1.
 Twenty-seven out of 32 subjects (84.4 
%) underwent all four treatments at least once 
(Figure-2). Twenty-nine individuals (90.6%) 
were still on follow-up at the last visit, while 3 
patients (9.3%) had stopped treatments because 
they desired a definitive solution for their NOD. 
All of them underwent bladder augmentation 
respectively after 5, 6 and 7 BoNT/A detrusor 
injections. At BD during follow-up, the mean 
bladder capacity at each catheterization ranged 
from 210-260mL, while mean episodes of daily 
incontinence varied from 2.39 to 2.96.
 For any BoNT/A type of treatments, the 
percentage of YES responses went from 19% 
with aboBoNT/A 500IU to 29% with onaBoNT/A 
300IU (Table-1).
 Only five (15.6%) patients reported at 
least 6 months of dryness after overall injec-
tions despite the BoNT/A used.
Occasional failure group
 Sixteen out of 60 subjects (26.6%) were 
defined “occasional failure” (OF). The mean du-
ration of efficacy in months for each BoNT/A 
treatment is reported in Figure-1.
 Five and two out of 16 subjects failed 
twice and three times during follow-up, respec-
tively.
 Eleven (68.7%) were treated by overall 
types and dosages of BoNT/A (Figure-2). Twelve 
out of 16 (75%) were still in follow-ups.
 Two out of 16 subjects (12.5%) stopped 
BoNT/A injections for non-urological compli-
cations. One required a permanent indwelling 
IBJU | LONG TERM BOTULINUM TOXIN A FOR NDO
724
Figure 1 - Boxplots reporting the effi cacy of treatments in the three groups of patients (left panel), and across all treatments 
used (right panel).
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catheter for an unsolved sacral sore lesion. One 
became unable to perform self-catheterization 
due to the onset of cerebrovascular disease. In-
stead 2 patients (12.5%) quit treatment, requir-
ing definitive alternatives for their NDO. As for 
the previous group, all these patients were sub-
mitted to enterocystoplasty.
 At BD during follow-up the mean blad-
der capacity at each catheterization ranged from 
230 to 265mL, whereas mean episodes of inconti-
nence/day varied from 2.15 to 2.79.
 Twenty-fi ve urodynamics were carried 
out within a three-month interval post-injec-


































Figure 2 - Random intercept models for each patient included in the study (The x-axis reports the different treatment used in the study whereas the y-axis reports 
the duration of the treatment expressed in month. Crosses report the predicted effi cacy for each treatment and for each patient, computed by using linear mixed-
effects models).
CF = Consecutive Failure; NF = No Failure; OF = Occasional Failure; Bot = OnaBoNT/A; Dys = AboBoNT/A
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 Low compliance was documented in the 
same five subjects (31.2%), both at baseline and 
during follow-ups.
 The percentage of YES responses ranged 
from18% with Dysport 500IU to 25% with Botox 
300IU (Table-1).
Consecutive failure group
 Twelve out of 60 individuals (20%) 
stopped BoNT/A injections due to consecutive 
failures. Nine out of 12 subjects (75%) report-
ed failure with the first injections. All these 
individuals quit the follow-up before March 
2013 (max follow-up 22 months). Two subjects 
(12.5%) were not on antimuscarinics at base-
line. Nine (75%) showed low compliance at uro-
dynamics (Table-2).
 The mean duration of efficacy in months 
for each BoNT/A treatment is reported in Figure-1.
 Thirty-five urodynamics were performed 
within 3 months following injection (range 8-12 
weeks).
 Mean MCC was 213.14mL (range 170-





0). The same nine patients 
with documented low compliance at baseline 




 The 10 patients using antimuscarinics at 
baseline never dropped their baseline dosage of 
oral treatment following each BoNT/A injection.










Total number of injections 202 162 96 79
Number of injections 6-months dry (%) 58 (29%) 44 (27%) 21 (22%) 15 (19%)
Occasional Failure group
Total number of injection 96 81 42 22
Number of injection 6-months dry (%) 24 (25%) 18 (22%) 8 (19%) 4 (18%)
Statistical results
 The CF group showed a pronounced dif-
ference in the duration of efficacy of the treat-
ments with an average two-months duration 
against eight-months reported for the other two 
groups (Kruskal-Wallis test p-value <0.01) (Fig-
ure-1). No significant differences were found in 
the three groups of patients regarding the type of 
treatments considered with an average duration of 
efficacy per group equal to the one reported above 
(Kruskal-Wallis test p-values >0.05) (Figure-1). In 
addition, the efficacy of treatments in the three 
groups of patients was assessed through Linear 
Mixed-Effects Models with random intercept, re-
porting a different regression model for each pa-
tient (Figure-2). Results showed that the efficacy 
of the treatments drastically changes in the three 
groups of patients considered, regardless of the 
type of treatment (p-values >0.05). Considering 
the predictable variables, only low compliance at 
baseline had a significant impact on determining 
consecutive failures (95% confident interval [CI] 
0.53-3.14; Odd Ratio [OR] 7.27; p value=0.006).
DISCUSSION
 According to our results, long term re-
sponse does not depend on the type of treatments. 
As a matter of fact, no significant differences in 
mean duration of efficacy between treatments 
were found in the overall sample. The mean clini-
cal efficacy was around 8 months as reported in 
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literature in shorter follow-ups using only one type 
of BoNT/A at the same or different dosages (14-17).
 Moreover, the switch option does not 
seem a valid strategy for failed patients. In the 
OF, patients responded to the same type and 
dosage of BoNT/A that had previously failed. 
Moreover, considering the CF, switching was 
not helpful to avoid a further “failure”. Al-
though, the number of CF patients was small, 
this group showed a higher percentage of low 
compliance at baseline urodynamics compared 
to others. This finding is similar to that report-
ed in literature (15, 21) and it could explain 
why CF discontinued follow-up earlier and 75% 
of them reported failure at first injection.
 Concerning the use of oral antimus-
carinics, whether they are useful to extend 
the interval between injections is still widely 
debatable. As a matter of fact the main RCTs 
were designed without antimuscarinic wash-
out (9, 11). In our study the percentage of YES 
responses was ≤30% in both OF and NF groups. 
Finazzi et al. reported a similar trend about the 
use of antimuscarinics during the first injection 
follow-up. In their prospective observational 
study on 105 patients, only 23.8% of patients 
discontinued oral therapy at 120 days, whereas 
almost 97% of patients were on antimuscarinics 
with a majority of them (52%) already having 
returned to oxybutinin t.i.d. within 6 months 
following 300IU BoNT/A treatment (22). Simi-
larly, Alvares et al. showed that 18 out of 22 
subjects (81.8%) continued to use anticholiner-
gics to achieve continence (23).
 In our sample, a high percentage of 
SCI patients (70.7%) has been in follow-up for 
Table 2 - Baseline characteristics of patients.
No Failure Occasional failure Consecutive failures
Total numbers of patients 32 16 12
Age in years (mean ± SD) 39.97 ± 10.79 37.62 ± 10.61 39.50 ± 9.07
Duration in months of SCL pre-first BoNT/A (mean ± SD) 41.03 ± 16.87 39.25 ± 17.32 33.83 ± 18.21
Nº with traumatic aetiology of SCL (%) 27 (84.4) 13 (81.2) 11 (91.6)
Nº of males (%) 25 (78.1) 12 (75) 8 (66.6)
Nº of tetraplegics (%) 7 (21.8) 5 (31.2) 4 (33.3)
Nº with complete SCL (%) 22 (68.7) 9 (56.2) 7 (58.3)
Nº on antimuscarinics (%) 27 (84.3) 11 (68.7) 10 (83.3)
3-day Bladder Diary
Bladder capacity in mL (mean ± SD)  203.12 ± 31.87 206.87 ± 34.89 193 ± 38
Episodes of daily urinary incontinence (mean ± 
SD)  
4.11 ± 0.75 3.83 ± 0.76 4.19 ± 0.75
Urodynamics
MCC in mL  (mean ± SD)  190.62 ± 28.62 168.12 ± 11.06 177.50 ± 28.30
Pdetmax in cmH
2
0 (mean ± SD)  64.40 ± 10.71 63.51 ± 12.07 66.50 ± 10.50
Compliance in mL/H
2
0 (mean ± SD)  26.19 ± 13.44 24. 74 ± 14.17 17.67 ± 20.47
SD = Standard deviation; Nº = Number of patients; BoNT/A = Botulinum Toxin A; SCI = spinal cord lesion; Pdetmax = maximum detrusor pressure at involuntary 
contraction; MCC = Maximum Cystometric Capacity
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longer than 15 years. Seventeen out 60 patients 
(12 of whom were CF) asked for bladder augmen-
tation (24, 25).
 This result raises the question whether or 
not treating subjects with BoNT/A for longer than 
15 years is the right approach.
 Nowadays, although the alternative option 
for treating refractory NDO is bladder augmenta-
tion, over the last 10 years other lesser invasive 
treatments have been proposed to selected SCI 
patients, such as sacral neuromodulation, which 
may also have potential positive effects on other 
concomitant pelvic dysfunctions (26). Our find-
ings (i.e. the need for continuative use of antimus-
carinics, the time duration of dryness, the vari-
ability in responsiveness and possible occurrence 
of occasional BoNT/A ineffectiveness) ought to 
be shared and discussed with patients at the time 
of counselling and at follow-ups. Thus, patients 
should be well informed from the beginning about 
the opportunity for alternative long term solutions 
which could guarantee dryness.
 We are aware that our study was de-
signed retrospectively and we could not determine 
whether some criteria were used to switch treat-
ment despite response. Considering this limit, our 
methodology requires further explanations. First-
ly, at the time of inclusion in 1999, no literature 
was available (4). Our policy since the beginning 
of our experience was exclusively to repeat the 
same BoNT/A when failure occurred once. This 
approach was chosen by the fact that we did not 
know the real individual response to one BoNT/A 
rather than another, in order to definitively ex-
clude one treatment before moving on to the next. 
Although our clinical behaviour and definition of 
non-responsiveness (CF) could be debatable, we 
think it was helpful to discriminate the occasional 
failure vs. non-responders and give stronger rea-
sons for recommending major surgery. Again, to 
that end, we always objectively documented fail-
ure through urodynamics.
CONCLUSIONS
 Long-term BoNT/A for NDO did not in-
crease failures, independent of the types of treat-
ments. Again, switching did not improve response 
(14, 27, 28). Non-responsiveness (CF) was found 
in short follow-ups despite switching, so patients 
should be promptly advised about other treatment 
options. The possibility of an indefinite treatment 
period using BoNT/A for other groups of patients 
does not seem impractical, but definition of long 
term response and/or criteria for discontinuing re-
petitive BoNT/A injections are urgent (29). Rand-
omized prospective comparative studies are need-
ed to confirm our results, especially in populations 
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